

Elena H MartÃ-nez-Lapiscina

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9226880/publications.pdf>

Version: 2024-02-01

77
papers

8,291
citations

159358

30
h-index

82410

72
g-index

79
all docs

79
docs citations

79
times ranked

11816
citing authors

#	ARTICLE	IF	CITATIONS
1	Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 188-195.	0.9	13
2	Oligoclonal IgM bands in the cerebrospinal fluid of patients with relapsing MS to inform long-term MS disability. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1706-1716.	1.4	8
3	Cortical fractal dimension predicts disability worsening in Multiple Sclerosis patients. <i>NeuroImage: Clinical</i> , 2021, 30, 102653.	1.4	21
4	APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies. <i>Neurology</i> , 2021, 97, 68-79.	1.5	96
5	In Vivo Molecular Changes in the Retina of Patients With Multiple Sclerosis. , 2021, 62, 11.		7
6	Retinal Optical Coherence Tomography in Neuromyelitis Optica. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	3.1	47
7	Dynamics and Predictors of Cognitive Impairment along the Disease Course in Multiple Sclerosis. <i>Journal of Personalized Medicine</i> , 2021, 11, 1107.	1.1	8
8	Healthy diet, depression and quality of life: A narrative review of biological mechanisms and primary prevention opportunities. <i>World Journal of Psychiatry</i> , 2021, 11, 997-1016.	1.3	16
9	Popularidad de Neurología en España: un análisis de la elección de la especialidad. <i>Neurología</i> , 2020, 35, 543-550.	0.3	6
10	Using Acute Optic Neuritis Trials to Assess Neuroprotective and Remyelinating Therapies in Multiple Sclerosis. <i>JAMA Neurology</i> , 2020, 77, 234.	4.5	17
11	Rebound of multiple sclerosis activity after fingolimod withdrawal due to planning pregnancy: Analysis of predisposing factors. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101483.	0.9	23
12	Case for a new corticosteroid treatment trial in optic neuritis: review of updated evidence. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 9-14.	0.9	22
13	Impact of Cognitive Reserve and Structural Connectivity on Cognitive Performance in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020, 11, 581700.	1.1	8
14	Retinal and brain damage during multiple sclerosis course: inflammatory activity is a key factor in the first 5 years. <i>Scientific Reports</i> , 2020, 10, 13333.	1.6	20
15	Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO). <i>BMJ Open</i> , 2020, 10, e035397.	0.8	10
16	Associations of serum 25(OH) vitamin D levels with clinical and radiological outcomes in multiple sclerosis, a systematic review and meta-analysis. <i>Journal of the Neurological Sciences</i> , 2020, 411, 116668.	0.3	26
17	Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosis. <i>Brain</i> , 2020, 143, 1127-1142.	3.7	29
18	Vitamin D, smoking, EBV, and long-term cognitive performance in MS. <i>Neurology</i> , 2020, 94, e1950-e1960.	1.5	45

#	ARTICLE	IF	CITATIONS
19	Trans Neuronal Retrograde Degeneration to OCT in Central Nervous System Diseases. , 2020, , 365-374.		0
20	Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731987158.	0.5	34
21	Remyelination: a good neuroprotective strategy for preventing axonal degeneration?. Brain, 2019, 142, 233-236.	3.7	8
22	Reporting of R2 Statistics for Mixed-Effects Regression Modelsâ€”Reply. JAMA Neurology, 2019, 76, 507.	4.5	5
23	Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study. Annals of Neurology, 2019, 85, 618-629.	2.8	104
24	Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 8463-8470.	3.3	112
25	Late-onset neuromyelitis optica spectrum disorder. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	3.1	44
26	Spanish validation of the telephone assessed Expanded Disability Status Scale and Patient Determined Disease Steps in people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 27, 333-339.	0.9	17
27	Frequency and relevance of IgM, and IgA antibodies against MOG in MOG-IgG-associated disease. Multiple Sclerosis and Related Disorders, 2019, 28, 230-234.	0.9	18
28	Identification and treatment of the visual processing asymmetry in MS patients with optic neuritis: The Pulfrich phenomenon. Journal of the Neurological Sciences, 2018, 387, 60-69.	0.3	5
29	Early retinal atrophy predicts long-term visual impairment after acute optic neuritis. Multiple Sclerosis Journal, 2018, 24, 1196-1204.	1.4	23
30	The International Multiple Sclerosis Visual System Consortium: Advancing Visual System Research in Multiple Sclerosis. Journal of Neuro-Ophthalmology, 2018, 38, 494-501.	0.4	15
31	A Healthy Diet for Your Heart and Your Brain. , 2018, , 169-197.		12
32	Assessing Biological and Methodological Aspects of Brain Volume Loss in Multiple Sclerosis. JAMA Neurology, 2018, 75, 1246.	4.5	32
33	Combined walking outcome measures identify clinically meaningful response to prolonged-release fampridine. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641878000.	1.5	7
34	Magnetic resonance markers of tissue damage related to connectivity disruption in multiple sclerosis. NeuroImage: Clinical, 2018, 20, 161-168.	1.4	22
35	Predictors of vision impairment in Multiple Sclerosis. PLoS ONE, 2018, 13, e0195856.	1.1	21
36	Monitoring the Course of MS With Optical Coherence Tomography. Current Treatment Options in Neurology, 2017, 19, 15.	0.7	40

#	ARTICLE	IF	CITATIONS
37	Impairment of decision-making in multiple sclerosis: A neuroeconomic approach. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1762-1771.	1.4	8
38	Structural networks involved in attention and executive functions in multiple sclerosis. <i>NeuroImage: Clinical</i> , 2017, 13, 288-296.	1.4	87
39	Precision medicine for multiple sclerosis: an update of the available biomarkers and their use in therapeutic decision making. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 345-361.	0.4	12
40	Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. <i>Lancet Neurology</i> , The, 2017, 16, 797-812.	4.9	397
41	Time is vision: The importance of the early discovery and diagnosis of optic neuritis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1806-1807.	1.4	2
42	Dynamics and heterogeneity of brain damage in multiple sclerosis. <i>PLoS Computational Biology</i> , 2017, 13, e1005757.	1.5	33
43	The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. <i>Neurology</i> , 2016, 86, 2303-2309.	1.5	331
44	Trans Neuronal Retrograde Degeneration to OCT in Central Nervous System Diseases. , 2016, , 205-214.		0
45	Phenytoin for neuroprotection. <i>Lancet Neurology</i> , The, 2016, 15, 901-902.	4.9	2
46	Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders. <i>Therapeutic Advances in Neurological Disorders</i> , 2016, 9, 436-440.	1.5	43
47	Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. <i>Lancet Neurology</i> , The, 2016, 15, 574-584.	4.9	266
48	Visual field impairment captures disease burden in multiple sclerosis. <i>Journal of Neurology</i> , 2016, 263, 695-702.	1.8	14
49	Pituitary-ovary axis and ovarian reserve in fertile women with multiple sclerosis: A pilot study. <i>Multiple Sclerosis Journal</i> , 2016, 22, 564-568.	1.4	36
50	Drug Trials in Neuroprotection. , 2016, , 171-184.		0
51	Knowledge Retrieval from PubMed Abstracts and Electronic Medical Records with the Multiple Sclerosis Ontology. <i>PLoS ONE</i> , 2015, 10, e0116718.	1.1	26
52	Improved Framework for Tractography Reconstruction of the Optic Radiation. <i>PLoS ONE</i> , 2015, 10, e0137064.	1.1	39
53	The analysis of semantic networks in multiple sclerosis identifies preferential damage of long-range connectivity. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 387-394.	0.9	9
54	Dynamics of retinal injury after acute optic neuritis. <i>Annals of Neurology</i> , 2015, 77, 517-528.	2.8	142

#	ARTICLE	IF	CITATIONS
55	Walking function in clinical monitoring of multiple sclerosis by telemedicine. <i>Journal of Neurology</i> , 2015, 262, 1706-1713.	1.8	22
56	Mediterranean Diet and Age-Related Cognitive Decline. <i>JAMA Internal Medicine</i> , 2015, 175, 1094.	2.6	653
57	Color vision impairment in multiple sclerosis points to retinal ganglion cell damage. <i>Journal of Neurology</i> , 2015, 262, 2491-2497.	1.8	35
58	The multiple sclerosis visual pathway cohort: understanding neurodegeneration in MS. <i>BMC Research Notes</i> , 2014, 7, 910.	0.6	26
59	Dynamic molecular monitoring of retina inflammation by <i>in vivo</i> Raman spectroscopy coupled with multivariate analysis. <i>Journal of Biophotonics</i> , 2014, 7, 724-734.	1.1	25
60	Is the incidence of optic neuritis rising? Evidence from an epidemiological study in Barcelona (Spain), 2008–2012. <i>Journal of Neurology</i> , 2014, 261, 759-767.	1.8	32
61	Trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis. <i>Annals of Neurology</i> , 2014, 75, 98-107.	2.8	206
62	Colour vision impairment is associated with disease severity in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1207-1216.	1.4	35
63	The visual pathway as a model to understand brain damage in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1678-1685.	1.4	45
64	Genotype patterns at CLU, CR1, PICALM and APOE, cognition and Mediterranean diet: the PREDIMED-NAVARRA trial. <i>Genes and Nutrition</i> , 2014, 9, 393.	1.2	58
65	Retrograde retinal damage after acute optic tract lesion in MS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 824-826.	0.9	22
66	Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. <i>New England Journal of Medicine</i> , 2013, 368, 1279-1290.	13.9	3,677
67	Virgin olive oil supplementation and long-term cognition: the Predimed-Navarra randomized, trial. <i>Journal of Nutrition, Health and Aging</i> , 2013, 17, 544-552.	1.5	216
68	Retinal periphlebitis is associated with multiple sclerosis severity. <i>Neurology</i> , 2013, 81, 877-881.	1.5	34
69	Mediterranean diet improves cognition: the PREDIMED-NAVARRA randomised trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1318-1325.	0.9	534
70	Cortico-juxtacortical involvement increases risk of epileptic seizures in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2013, 128, 24-31.	1.0	33
71	Natalizumab-induced autoimmune hepatitis in a patient with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1234-1235.	1.4	13
72	Reply to the letter to the editor by Lucena Romero et al. on the article ‘Epileptic seizure and lipoma of corpus callosum: Cause or incidental finding’. <i>Neurologia (English Edition)</i> , 2012, 27, 58-59.	0.2	0

#	ARTICLE	IF	CITATIONS
73	Myasthenia gravis: Sleep quality, quality of life, and disease severity. Muscle and Nerve, 2012, 46, 174-180.	1.0	50
74	Epileptic seizure and lipoma of corpus callosum: cause or incidental finding. Neurología (English) Tj ETQq0 0 0 rgBT, Overlock 10 Tf 50	0.2	1
75	Nut consumption and incidence of hypertension: The SUN prospective cohort. Nutrition, Metabolism and Cardiovascular Diseases, 2010, 20, 359-365.	1.1	45
76	Mediterranean diet and the incidence of cardiovascular disease: A Spanish cohort. Nutrition, Metabolism and Cardiovascular Diseases, 2010, 21, 237-44.	1.1	133
77	Retinal inflammation in multiple sclerosis revealed by optical coherence tomography and ophthalmoscopy. , 0, , 176-183.		0